That is, concomitant genetic ablation of Chrm1 in Chrm3-/- mice appeared to mitigate reductions in both colon tumor number and volume that we repeatedly observed in AOM-treated Chrm3-/- compared to WT mice (Figure 2A-D) [19]. The gene discussed is CHRM1; the disease is colonic neoplasm.